eli lilly

Apple (NASDAQ: AAPL) seems to be in a sphere all by itself these days, and its fiscal second-quarter results no doubt will be the highlight of the earnings reports due this week. However, others also on tap this week to share their results for the most recent quarter include Amazon.com (NASDAQ:...

While the fate of the 2010 health care reform law may rest in the hands of the Supreme Court, the nation's focus on health care has returned for the moment. For investors, the following health care picks all pay a dividend and have seen double-digit percentage growth in their share price since the...

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

Lots more earnings are on the schedule for this week, even as the calendar page turns. Look for quarterly results to come from Exxon Mobil (NYSE: XOM), Hershey (NYSE: HSY), Kellogg (NYSE: K), MasterCard (NYSE: MA), Northrop Grumman (NYSE: NOC) and United Parcel Service (NYSE: UPS). Analysts expect...

Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...

Bank of America has published a report on Eli Lilly & Co (NYSE: LLY). In the report, Bank of America wrote, "A large majority of docs (72%) expect their TRT prescribing to grow over the next year, while the rest expect stable prescribing. Rising patient awareness, testing, and new drugs were...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

Citi has put out a report on Eli Lilly (NYSE: LLY). In the report, Citi commented that, "Our 2Q11 EPS is $1.20 (+5% YOY), above the Street's $1.17. We model 2Q11 revenue of $6.05B (+5%), above the Street's $5.99B. We project US and international sales of $3.29B (+1%) and $2.76B (+11%, assuming a...

Earnings season ramps up this week with quarterly reports due from the likes of tech companies such as IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT), big banks such as Wells Fargo (NYSE: WFC) and Bank of America (NYSE: BAC), and consumer goods giants such as PepsiCo (NYSE: PEP) and Johnson &...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Wells Fargo is out with its report today on Eli Lilly (NYSE: LLY), maintaining Market Perform. In a note to clients, Wells Fargo writes, "Investor day highlights pipeline candidates in diabetes, oncology, neurology, and autoimmune. Management reiterated 2011-14 minimum annual guidance of $20B in...

According to Citi, Eli Lilly (NYSE: LLY) will host its investment community meeting on June 30th in New York City. Citi said that the focal point of the meeting is on LLY's updated 2014 minimum guidance, which incorporates the impact of US healthcare reform, EU pricing austerity, earlier than...

Citi is maintaining its Hold rating on shares of Eli Lilly (NYSE: LLY). “LLY announced results for its fully humanized GLP-1 Fc (LY2189265) thorough QT (tQT) analysis at the American Diabetes Association meeting in San Diego. In a single-dose study of supratherapeutic GLP-1Fc doses in health...

Forest Laboratories (NYSE: FRX) and Watson Pharmaceuticals (NYSE: WPI) reached new 52-week highs of $40.52 and $66.00 per share, respectively, in Wednesday's trading session. Forest Labs saw an upgrade from Argus and Duncan-Williams upgraded its price target on the stock to $45 in the wake of...

Colgate-Palmolive (NYSE: CL) and Forest Laboratories (NYSE: FRX) reached new 52-week highs of $89.28 and $39.56 per share, respectively, late in Monday's trading session. Colgate just announced the completion of its purchase of the Sanex personal care brand from Unilever (NYSE: UL). Colgate has a...